Your browser is no longer supported. Please, upgrade your browser.
SLDB Solid Biosciences Inc. weekly Stock Chart
SLDB [NASD]
Solid Biosciences Inc.
Index- P/E- EPS (ttm)-2.65 Insider Own4.70% Shs Outstand48.06M Perf Week-6.27%
Market Cap134.04M Forward P/E- EPS next Y-1.05 Insider Trans0.00% Shs Float26.55M Perf Month1.70%
Income-114.30M PEG- EPS next Q-0.50 Inst Own57.60% Short Float7.58% Perf Quarter42.38%
Sales- P/S- EPS this Y-29.40% Inst Trans-0.91% Short Ratio6.03 Perf Half Y-29.65%
Book/sh1.17 P/B2.56 EPS next Y36.00% ROA-113.00% Target Price4.17 Perf Year-42.39%
Cash/sh1.20 P/C2.50 EPS next 5Y- ROE-142.20% 52W Range1.96 - 13.58 Perf YTD-32.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.98% Beta-
Dividend %- Quick Ratio4.50 Sales past 5Y- Gross Margin- 52W Low52.55% ATR0.24
Employees121 Current Ratio4.50 Sales Q/Q- Oper. Margin- RSI (14)46.90 Volatility7.00% 8.98%
OptionableYes Debt/Eq0.02 EPS Q/Q34.70% Profit Margin- Rel Volume0.44 Prev Close3.00
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume333.83K Price2.99
Recom2.90 SMA20-3.75% SMA503.21% SMA200-37.30% Volume146,601 Change-0.33%
May-07-20Downgrade Evercore ISI Outperform → In-line
Oct-11-19Initiated Evercore ISI Outperform $22
Aug-29-19Downgrade Citigroup Neutral → Sell $6
Aug-19-19Upgrade SVB Leerink Mkt Perform → Outperform $8 → $15
Aug-16-19Upgrade Chardan Capital Markets Neutral → Buy $7.50 → $10
May-14-19Downgrade Goldman Neutral → Sell $5 → $4
May-14-19Downgrade Credit Suisse Neutral → Underperform $7 → $6
Feb-08-19Upgrade Citigroup Sell → Neutral $8
Feb-08-19Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-18Initiated Citigroup Sell
Sep-06-18Initiated Credit Suisse Neutral $38
Jul-05-20 05:27PM  
Jun-18-20 07:00AM  
Jun-12-20 06:45AM  
May-29-20 08:35AM  
May-22-20 07:00AM  
May-14-20 07:00AM  
May-13-20 09:49AM  
May-11-20 03:03AM  
May-09-20 01:48PM  
May-07-20 07:22AM  
Apr-16-20 07:00AM  
Mar-12-20 07:00AM  
Jan-31-20 05:00AM  
Jan-22-20 11:48AM  
Jan-10-20 10:08AM  
Jan-09-20 08:00AM  
Dec-23-19 10:11AM  
Dec-19-19 06:08PM  
Dec-18-19 08:46AM  
08:38AM  
06:30AM  
Dec-16-19 08:52AM  
Dec-13-19 08:55AM  
Nov-20-19 01:28PM  
Nov-13-19 03:43PM  
Nov-12-19 05:51PM  
04:03PM  
10:56AM  
10:22AM  
10:15AM  
07:00AM  
06:45AM  
Oct-16-19 08:42AM  
Oct-02-19 07:30AM  
Sep-03-19 02:21PM  
Aug-29-19 11:38AM  
09:02AM  
Aug-27-19 07:23AM  
Aug-20-19 12:20PM  
12:02PM  
10:03AM  
Aug-19-19 03:17PM  
08:58AM  
Aug-16-19 12:15PM  
Aug-15-19 02:41PM  
Aug-14-19 07:25AM  
Aug-08-19 10:33AM  
Jul-26-19 07:25AM  
Jul-01-19 09:35AM  
09:21AM  
Jun-28-19 06:51PM  
04:28PM  
Jun-12-19 04:04PM  
Jun-06-19 06:10PM  
May-16-19 03:00PM  
10:00AM  
May-14-19 04:27PM  
01:56PM  
12:26PM  
11:51AM  
07:42AM  
May-13-19 04:10PM  
May-03-19 10:13AM  
Apr-17-19 11:10AM  
Apr-16-19 02:39PM  
Apr-15-19 04:01PM  
Apr-08-19 09:45AM  
Mar-28-19 10:20AM  
Mar-13-19 07:30AM  
Mar-10-19 10:36AM  
Feb-27-19 09:53AM  
Feb-26-19 11:15AM  
08:54AM  
Feb-25-19 03:12PM  
Feb-20-19 03:52PM  
Feb-15-19 08:56AM  
Feb-07-19 08:37PM  
04:11PM  
01:47PM  
11:22AM  
11:05AM  
10:45AM  
09:42AM  
09:25AM  
06:45AM  
Jan-02-19 08:00AM  
Nov-21-18 07:45AM  
Nov-13-18 07:00AM  
Nov-09-18 07:30AM  
Oct-25-18 07:30AM  
Oct-05-18 04:05PM  
Oct-01-18 08:00AM  
Sep-13-18 07:30AM  
Sep-06-18 02:47PM  
Aug-30-18 02:00PM  
12:47PM  
Aug-10-18 07:30AM  
Aug-01-18 10:03AM  
Jul-26-18 10:30AM  
Jul-05-18 03:19PM  
Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.